| Literature DB >> 14601525 |
João Nuno Moreira1, Sérgio Simões.
Abstract
NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14601525
Source DB: PubMed Journal: Curr Opin Mol Ther ISSN： 1464-8431